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Abstract On 18 July 2014, the National Institute of
Mental Health in collaboration with ViiV Health Care
and Boehringer Ingelheim supported a symposium on
HIV eradication and what it meant for the brain. The
symposium was an affiliated event to the 20th Interna-
tional AIDS Conference. The meeting was held in Mel-
bourne, Australia, and brought together investigators
currently working on HIV eradication together with in-
vestigators who are working on the neurological com-
plications of HIV. The purpose of the meeting was to
bring the two fields of HIV eradication and HIV neu-
rology together to foster dialogue and cross talk to
move the eradication field forward in the context of
issues relating to the brain as a potential reservoir of
HIV. The outcomes of the symposium were that there
was substantive but not definitive evidence for the brain
as an HIV reservoir that will provide a challenge to
HIV eradication. Secondly, the brain as a clinically sig-
nificant reservoir for HIV is not necessarily present in
all patients. Consequently, there is an urgent need for
the development of biomarkers to identify and quantify
the HIV reservoir in the brain. Lastly, when designing
and developing eradication strategies, it is critical that
approaches to target the brain reservoir be included.
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Introduction
On 18 July 2014, the National Institute of Mental Health in
collaboration with ViiV Health Care and Boehringer
Ingelheim supported a symposium affiliated with the 20th
International AIDSConference. This symposiumwas directed
at HIVeradication in relation to the brain. The purpose of the
meeting was to bring the two fields of HIV eradication and
HIV neurology together to foster dialogue and cross talk to
move the eradication field forward in the context of the brain
as a potential reservoir of HIV.
The symposium was divided into six sessions, the first
being Eradication: Theory and Practice, the second, Eradica-
tion and the Central Nervous System (CNS) Model Systems
Including Cells and Animal Models. The third session was
devoted to the Brain as a Reservoir and Sanctuary, the fourth
was devoted to oral presentations from the attendees. The fifth
session identified the Risks and Outcomes of CNS Eradica-
tion, and the last was devoted to Current and Future Studies.
Session 1: eradication: theory and practice
This session provided a theoretical overview of eradication by
Dr Margolis followed by a review of whether the brain is a
problem for HIV eradication by Dr Deeks.
Dr Margolis began by reflecting on Timothy Brown, the
only person known to be cured of HIV infection. Mr Brown
was treated for leukemia with two stem cell bone marrow
transplants (BMT) and preconditioning that included chemo-
therapy and total body irradiation (Hutter et al. 2009). Nota-
bly, his donor was a CCR5 delta-32 homozygote (Mr Brown
was a delta-32 heterozygote). Mr Brown’s clinical course was
complicated by graft versus host disease (Hutter et al. 2009).
He has been off combination antiretroviral therapy (cART)
since 2009 without evidence of viral replication, or latent
HIV infection. Dr Margolis reflected on two other HIV posi-
tive (HIV+) persons who had ceased cART following success-
ful BMT therapy (the so-called “Boston patients”) and who
have remained in HIV remission without detectable plasma
RNA or cell-associated DNA for a period of 12 and 32 weeks
before experiencing HIV virological rebound (Henrich
et al. 2014). He also noted that just prior to the World
AIDS 2014 conference, “the Mississippi baby” whose cART
had been ceased at 18 months of age, had developed HIV
rebound approximately 2 years following cART cessation
(Butler et al. 2014).
Dr Margolis then gave “the T-cell centric view” of the first
steps towards HIVeradication. Latent HIV infection is present
predominantly within central memory resting CD4+ T cells,
but also within other T-cell types. When latently infected cells
are activated they produce low-level plasma viremia, which is
detectable in cART-suppressed individuals using an ultrasen-
sitive single copy RNA assay. Dr Margolis stated that one of
the first steps in eradicating HIV infection is to develop
an anti-latency strategy to stimulate latently infected T
cells to (at least) produce HIV antigen so that the im-
mune system could target and kill these cells (Archin
et al. 2014). He noted that over the past 1–2 years
strategies involving immunotherapy have being devel-
oped (Barouch and Deeks 2014) to complement the
anti-latency strategies.
Theoretically, following the administration of the
abovementioned treatment strategies in HIV+ patients, Dr
Margolis noted that we would still be faced with a number
of uncertainties, all of which are fully relevant to the brain,
perhaps the most important being the challenge of achieving
clearance of all infected cells.
With respect to the CNS, Dr Margolis noted that, as is seen
in the plasma of treated HIV+ patients on virologically sup-
pressive cART, very low-level residual viremia is detectable in
the cerebrospinal fluid (CSF). He noted that while there is the
challenge of achieving adequate antiretroviral drug penetra-
tion into the CNS (Letendre et al. 2010), a CNS antiretroviral
intensification study using raltegravir failed to reduce low-
level CSF viremia (Dahl et al. 2011) similar to other studies
undertaken in the periphery (Gandhi et al. 2012; Llibre et al.
2012). Therefore, Dr Margolis stated that he was not sure that
finding low levels of HIV RNA in the CSF is very different
from finding low-level HIV RNA in the periphery, or other
tissues. With respect to this, he observed that the brain does
have long-lived tissue macrophages (microglia) that might
harbor HIV latently. Notwithstanding, he noted, as did several
other speakers on the day, that the hypothesis that the CNS
serves as a reservoir site for HIV remains to be conclusively
proven.
Were this found to be the case, the issue of achieving ef-
fective antiretroviral CNS penetrance would be important and
Dr Margolis highlighted some research directed towards pro-
viding cART via nanoformulations to enhance their CNS
levels (Dou et al. 2009).
The issue of establishing an ideal model to study HIV per-
sistence in different tissues including the brain was discussed
(Dinoso et al. 2009). Dr Margolis noted that primates can now
be successfully virologically suppressed on cART and in sev-
eral laboratories, primates who have received suppressive
cART for 2–3 years, are being studied to determine the pres-
ence of HIV tissue reservoirs including the CNS. Humanized
mice models are being used also to study CNS reservoirs
(Denton et al. 2012).
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Dr Margolis then reviewed some of the latency reversing
agents (LRAs) being evaluated to activate latently infected
cells. His group has studied the histone deacetylase (HDAC)
inhibitor vorinostat and found that it increased the levels of
HIV gag RNA in resting CD4+ T cells of eight HIV+ patients
(Archin et al. 2012a). Work undertaken by Bullen et al. found
that none of several LRAs, including vorinostat, induced viral
outgrowth from latent reservoirs of HIV+ patients on suppres-
sive cART (Bullen et al. 2014). Only one highly toxic LRA,
bryostatin, caused significant fold increases in HIV mRNA
both intracellularly and in the culture supernatant of the pa-
tients’ resting CD4+ T cells in one study (Bullen et al. 2014).
Future work will therefore examine the efficacy of combin-
ing different LRAs to activate latent HIV cellular reservoirs.
Dr Margolis discussed work being done by different pharma-
ceutical companies including Merck and Gilead to screen
compounds for their ability to reverse HIV latency. Dr Hazuda
at Merck has been evaluating farnesyltransferase inhibitors
(FTIs), which alone, or in combination with vorinostat appear
to increase expression of HIV in latent HIV reservoirs. FTIs
will be evaluated in animal models in the future.
Dr Margolis then discussed the important question of
whether serial treatments with LRAs or combination LRA
treatment will be necessary to purge HIV fully from all cellu-
lar and tissue reservoirs. This seems likely because it appears
that a cascade of molecular events must occur at the HIV
promoter for transcription to occur, some of which happen
by “chance” or in a “stochastic”manner. Hence, he noted that
serial treatments, using different combinations, might be nec-
essary to fully clear HIV reservoirs, akin to the approach un-
dertaken with cancer chemotherapy.
DrMargolis then referenced the very sobering, recent work
undertaken in Robert Siliciano’s laboratory (Ho et al. 2013),
which compounds the challenges faced by the HIV cure field.
Here, Ho et al. showed that a proportion of the viruses that had
previously been thought defective because they could not be
induced from patients’ latent CD4+ cell reservoirs following
in vitro activation, are in fact replication competent (Ho et al.
2013). Ho et al. estimate that the size of the replication-
competent HIVreservoir is up to 60-fold greater than had been
previously estimated (Ho et al. 2013).
Dr Margolis noted that in various cell populations includ-
ing those within the brain, some of the drugs’ targets might be
different and documenting this will be important if we need to
target cells in the brain. For example, macrophages versus T
cells have much higher levels of HDAC8 enzymes than the
HDAC 1–3 enzymes that predominate in T cells. Hence, the
field will need to know whether HDAC inhibitors used in
clinical trials will target HDACs in different cell types, includ-
ing microglia and brain macrophages.
Turning to clinical treatment trials in human subjects, Dr
Margolis felt that it will be hard to harvest meaningful CNS
samples from patients hence the use of magnetic resonance
spectroscopy imaging and gold standard serial neurocognitive
testing will be important to elucidate the impact of different
treatment strategies upon the CNS.
In closing, Dr Margolis said that although the brain is chal-
lenging because of the difficulty in obtaining samples and the
brain’s different cell types, that his approach to “attacking”
persistent neuro HIV infection is identical to his approach to
persistent systemic HIV infection. Studies need to be under-
taken in cell lines, primary cell models, patients’ cells, animal
models, and patients. He stated that we need to approach the
issue of persistent viremia in resting CD4+ T cells and deter-
mine which other cells contribute to ongoing low-level viral
replication and identify drugs that can extinguish this replica-
tion. With respect to persistent provirus in resting CD4+ cells
and other possible cell types, he stated that we will continue to
study HDAC inhibitors, and other novel anti-latency agents
singly and in combination.
Dr Deeks offered “an agnostic perspective” of whether the
CNS can serve as an HIV reservoir for HIV+ persons receiv-
ing virologically suppressive, long-term cART. He posed the
following four questions to provide an overview of his “ag-
nostic perspective”.
Does HIV reside in the CNS during long-term cART?
Dr Deeks noted that in both humans and SIV primate models,
HIV infects the brain during primary HIV infection and during
untreated HIV/SIV infection. Dr Deeks referred to the work of
Schnell et al. demonstrating that genetically distinct HIV var-
iants exist in the CNS and plasma (Schnell et al. 2011). He
also cited Dahl et al. who showed that in patients with HIV-
associated dementia (HAD), genetically diverse macrophage-
tropic and R5 T-cell-tropic viruses are present in the CSF and
evince slow and rapid decay kinetics, respectively following
cART commencement (Dahl et al. 2014a). The findings of
Dahl et al. suggest that there are long-lived cells in the CNS
that are a source of HIV replication.
He noted that the answers to the questions as to which cell
types may harbor HIV in the CNS and the nature of the cell
turnover and persistence of these cellular reservoirs are not
known definitively at this time.
Dr Deeks stated that in his opinion, the strongest evidence
for the existence of a CNS HIV reservoir is the data from
individuals who are clinically asymptomatic and have plasma
HIV RNA <50 copies/ml, but in their CSF have detectable
HIV (>50 copies/ml). He noted that several abstracts from
CROI 2014 reported on this phenomenon of asymptomatic
CSF escape, with rates ranging from 10–23 %. Of note, a
published report by Eden et al., found that 10 % of 69 asymp-
tomatic persons had evidence of CSF escape with a median
detectable CSFHIV viral load of 121 copies/ml [IQR 54–213]
(Eden et al. 2010). These patients versus those without CSF
escape had higher levels of CSF neopterin. Notably, drug
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resistance could not be excluded as a cause of CSF escape
because levels of CSF virus were too low to perform resis-
tance genotyping (Eden et al. 2010).
More recently, in 49 HIV+ patients with HIV viral load
measurements <40 copies/ml by conventional assays in both
plasma and CSF, 17 % of patients had HIV detectable in their
CSF using ultrasensitive, single-copy assays (median <0.3
copies/ml [IQR 0.2–2.9]). Importantly, CSF and plasma levels
of HIV RNAwere not correlated in paired samples and levels
of CSF neopterin were significantly higher in those patients
with versus without detectable CSF HIV RNA (Dahl et al.
2014b). These data provide further evidence that HIV cellular
reservoirs may be present in the CNS and that low-level CSF
RNA is associated with CNS inflammation (Dahl et al.
2014b).
Does HIV replicate in the CNS during cART?
Dr Deeks noted that there is evidence for low-level, peripheral
HIV replication occurring in some patients. These data come
from studies undertaken in treated, virologically suppressed
patients in whom the integrase inhibitor, raltegravir had been
added to “intensify” their treatment regimens (Buzon et al.
2010; Hatano et al. 2013). In a proportion of these patients,
an increase in the level of HIV DNA 2LTR circles within
PBMCs was observed, suggesting that raltegravir had
prevented unidentified low-level HIV viral replication from
completing its integration into the host DNA (Buzon et al.
2010; Hatano et al. 2013).
As noted by Dr Margolis, one CSF raltegravir intensifica-
tion study has been undertaken in 14 patients whereupon
raltegravir did not reduce CSF HIV RNA levels, nor did it
reduce markers of intrathecal immune activation (Dahl et al.
2011). However, Dr Deeks noted that studies aimed at proving
that active HIV replication is occurring in the CNS by using
integrase inhibitor intensification and observing levels of
2LTR circles have not been undertaken. Therefore, the field
currently does not know if persistent viral replication occurs in
the CNS during suppressive cART.
Does inflammation persist in the CNS on treatment
and is it caused by CNS infection?
Dr Deeks referred to studies providing evidence that in the
periphery, the HIV reservoir size correlates with levels of in-
flammation and therefore, a priori, this could be true in the
CNS (Barouch and Deeks 2014). More recently, a paper from
his group has reported that there is an association between
markers of T-cell activation and proliferation and HIV persis-
tence (Cockerham et al. 2014).
With respect to the possible persistence of inflammation in
the brain, Dr Deeks cited work by Garvey et al. who used
[11C]-PK11195 positron emission tomography (PET) brain
scanning in seven effectively treated HIV+ patients (Garvey
et al. 2014). [11C]-PK11195 is a marker of a translocator pro-
tein, which is expressed by activated microglia. The authors
found a significant increase in activated microglia in HIV+
versus HIV negative controls and that greater [11C]-
PK11195 binding was associated with decreased executive
function in HIV+ patients (Garvey et al. 2014). Dr Deeks also
cited other work that described increased levels of activated
microglia in postmortem studies of virologically suppressed
patients (Anthony et al. 2005). Including the studies cited
above where low levels of HIV RNA in the CSF were asso-
ciated with higher levels of neopterin (Eden et al. 2010; Dahl
et al. 2014b), Dr Deeks felt that these albeit indirect data
indicate that there is virus replicating in the CNS which stim-
ulates CNS macrophages to produce neopterin, and thereby
provides further supportive data that the brain is an HIV
reservoir.
Can studies of systemic macrophage infection inform
what is happening in the CNS?
Dr Deeks then turned to the question of whether macrophages
serve as reservoirs of HIV. The current debate about the po-
tential for macrophages to be a reservoir revolves around the
fact that because macrophages phagocytose HIV-infected T
cells, any HIV DNA found in the macrophages may simply
be remnants of phagocytosis, presenting a technical difficulty.
He cited a number of studies including work done by Mario
Stevenson showing that DNA can be identified in alveolar
macrophages of HIV+ patients on long-term treatment
(unpublished).
Dr Deeks referred to the work of Dr Yukl where it has been
consistently shown that there are non-CD4+ T-cell leukocytes
that harbor HIV DNA and RNA, especially in the gut (Yukl
et al. 2013) and that these may be macrophages. He also re-
ferred to other unpublished studies by Hsue et al. and Courier
et al. that corroborate a potential role for macrophages as
reservoirs for HIV in the periphery, which would favor the
possibility that this may be the case in the CNS also.
Session 2: eradication and the CNS model systems
including cell and animal models
The first part of this session dealt with cell-based systems and
commenced with latency in the macrophage and microglial
cell by Dr Crowe followed by latency in the astrocyte by Dr
Churchill. The session finished with latency and the neuron
presented by Dr Spencer.
Dr Crowe addressed the important question of monocytes,
microglia, and latency and, prefaced her talk by stating that
she remains to be convinced that monocytes and microglia do
serve as reservoirs for latent HIV infection.
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Dr Crowe discussed several myeloid cell types that are
present within the CNS including parenchymal microglia,
perivascular and meningeal macrophages, choroid plexus
macrophages, and trafficking blood monocytes (Prinz and
Priller 2014). The turnover of these cells differs significantly
with brain microglia persisting for years compared with a 2–
3 month turnover of perivascular macrophages (Prinz and
Priller 2014).
Until lately it was thought that all the above-mentioned
cells were of the same myeloid origin. However, recent data
from studies in mice show that microglia are likely to arise
from uncommitted erythromyeloid stem cells in the yolk sac
unlike the other CNS macrophages which arise from
hematopoetic stem cell precursors in the fetal liver and embry-
onic aorta-gonad-mesonephros region and, postnatally, within
the bonemarrow (Prinz and Priller 2014). In humans, a similar
pattern of development occurs with microglia first being de-
tected in the spinal cord at 9 weeks, followed by a major influx
at 16 weeks, and it is not until 35 weeks that a fully differen-
tiated population of microglial cells can be discerned in the
human brain (Prinz and Priller 2014).
Dr Crowe made the important observation that adult and
fetal microglial cell lines have been used in different published
studies, which make comparison between studies difficult,
given the different distribution and biology of these cells in
adults and fetuses.
Dr Crowe then turned to the important question of which
cells in the brain can be productively infected with HIV.
Perivascular macrophages, microglia, and astrocytes are all
susceptible to infection but only the former two cell types
permit productive infection (Gonzalez-Scarano and Martin-
Garcia 2005). Perivascular macrophages are the main target
for HIV in humans and are the chief target for SIV in non-
human primates (Williams et al. 2001). In macaques, the den-
sity of SIV infection can vary in different areas of the brain,
which may confound some studies depending on where brain
tissue has been sampled and the number of sites biopsied. SIV
DNA can be detected throughout SIV infection in macaques,
but RNA is only present during acute HIV infection and dur-
ing SIV encephalitis (Williams et al. 2001). In patients with
HIVencephalitis, compared with appropriate controls, there is
an accumulation of CD14+ CD16+ monocytes and
perivascular macrophages within microglial nodules with
p24Ag localization within these cells (Fischer-Smith et al.
2001).
Dr Crowe then reviewed the principles of latency in terms
of their application in HIV infection, noting that a latently
infected cell does not produce infectious virus, but that the
cell’s state of latency must be reversible. She noted that the
cell types that putatively support latent HIV infection include
resting memory CD4+ T cells, monocytes, macrophages, as-
trocytes, and hematopoietic stem cells.While being convinced
that memory CD4+ Tcells support latency, Dr Crowe said that
there is only limited evidence that monocytes and macro-
phages may serve as latent HIV reservoirs. Monocytes are
short-lived cells that transform into macrophages within a
few days and hence their brief longevity technically precludes
their capacity to serve as long-acting reservoirs.
Dr Crowe noted that monocytes are widely perceived to
serve as reservoirs for HIV because replication-competent
HIV can be recovered from patients receiving effective long-
term cART (McElrath et al. 1991; Sonza et al. 2001) and
because they transform into macrophages. However, it has
not yet been proven that monocytes harbor latent HIV infec-
tion in virologically suppressed individuals on cART and, if
so, the frequency of latent infection.
As an aside, Dr Crowe added that if macrophages are cel-
lular reservoirs for HIV then this poses a considerable chal-
lenge to inducing HIV remission and cure because of their
longevity and their (and microglia’s) relative capacity to resist
apoptosis.
Dr Crowe highlighted another reason supporting the con-
cept that cells other than resting CD4 T+ cells serve as HIV
reservoirs: when HIV+ patients have rebound HIV viremia
upon ceasing cART, the rebounding virus is genetically dis-
tinct from that found in CD4+ reservoirs (Chun et al. 2000)
suggesting that the rebounding virus may be coming from
other cellular and/or tissue reservoirs. Phylogenetic analyses
provide evidence that monocytes produce low levels of virus
that can be identified in plasma in virologically suppressed
HIV+ patients (Zhu et al. 2002). CD14+ CD16+ positive
monocytes versus CD14+ CD16− monocytes preferentially
harbor infectious virus and HIV DNA in patients receiving
cART (Ellery et al. 2007).
Monocytes are harder to infect thanmacrophages, noted Dr
Crowe. Although they have the same manner of cell entry and
uncoating of the nuclear capsid, the synthesis of full-length
cDNA is inefficient in monocytes (Sonza et al. 1996). Other
factors may restrict susceptibility to HIV infection in mono-
cytes eg miRNAs and cellular host restriction factors includ-
ing APOBEC3G (apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like 3G), a family of proteins that play
an important role in innate antiviral activity that restrict HIV
replication in resting T cells (Chiu et al. 2005). Of note,
CD14+ CD16+ monocytes contain an inactive form of
APOBEC3G (Ellery et al. 2007).
The molecular mechanisms proposed that might permit
HIV latency to occur in monocytes and macrophages were
outlined by Dr Crowe who described them as complex. These
include changes in chromatin, cellular restriction factors, and
the lack of functional Tat.
Dr Crowe then turned to the question “Are monocytes la-
tently infected with HIV?” She noted that supportive data
come mostly from older studies. One study showed that fresh-
ly isolated monocytes from HIV+ persons harbored DNA but
not RNA (Mikovits et al. 1992). Another study reported that
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infectious virus was produced when monocytes were co-
cultured with activated T cells and that HIV DNA could be
detected in 74 % of monocytes, although no data were pro-
vided on HIV RNA or other viral proteins (McElrath et al.
1991). However, Dr Crowe noted that it is not clear how pure
the cell populations were in these studies, nor how robust the
available PCR assays were.
Turning to the brain, Dr Crowe noted that circular 1-LTR
DNA (Teo et al. 1997) and unintegrated DNA have been
found in the brains of AIDS patients with HIVE. In one im-
portant Australian study, Thompson et al. using laser capture
microdissection were able to demonstrate HIV DNA in mi-
croglia, perivascular macrophages, and astrocytes (Thompson
et al. 2011). They used the absence of p24 antigen positivity
on immunohistochemistry to denote that there was no produc-
tive infection in these brains (Thompson et al. 2011). Howev-
er, Dr Crowe felt that today, we would require the absence of
HIV RNA to be more confident about whether or not produc-
tive HIV infection was present.
Dr Crowe cautioned there are several issues that make
interpreting the published data and undertaking research into
latent HIV infection and microglia fairly difficult: definitions
of latency may differ, hence results need to be carefully
interpreted; many studies do not simultaneously examine
HIV DNA, HIV RNA, and productive infection; there is a
low frequency of HIV infection and integration in monocytes;
the purity of cell populations (contamination with other cells)
as well as the sensitivity of PCR techniques are important
considerations; the location of brain tissue macrophages and
microglia makes sampling of sites difficult and premortem
biopsies frequently come from a single CNS site; the time
from death to postmortem often limits RNA analyses. To
add to these difficulties, Dr Crowe noted that adult human
microglia from surgically removed brain tissue are scarce;
fetal microglia differ from adult cells, there is no consensus
on immunophenotypic markers for identification of microglia
and the immunophenotype of resting and activated microglia
differs. Some researchers thus choose the easier but far less
biologically relevant route of using U1 pro-monocytic cell
lines for studies of latency in monocytes.
In summarizing, Dr Crowe said she considered that it is still
controversial whether true HIV latency exists in monocytes,
macrophages, and microglia but it is likely, albeit unproven,
that the majority of HIV+ cART-suppressed patients have res-
ervoirs of infected cells that are transcriptionally silent in their
bone marrow, thymus, and brain. Importantly, the molecular
mechanisms regarding the establishment and maintenance of
latency in monocytes, macrophages, and microglia remain
unclear and that more rigorous studies are needed to elucidate
these issues.
Dr Spencer was tasked with discussing HIV latency in the
brain and therein whether CNS latency has an impact on neu-
ronal function.
Dr Spencer began by providing a current overview of HIV
treatment in middle- and high-income countries where people
live with virologically controlled, chronic HIV infection. He
noted that in older HIV+ populations HAND and neurodegen-
erative disorders are more frequently observed. At post
mortem, these patient populations may have higher levels of
protein misfolding and aggregation in the CNS with an accu-
mulation of A-β protein,α-synuclein, and p-tau. The levels of
A-β protein, p-tau, and α-synuclein are higher in older HIV+
patients, similar to those seen in HIV negative patients with
Alzheimer’s disease and Parkinson’s disease, respectively. In
gp120 transgenic mice, high levels of A-β protein and p-tau
are seen suggesting that the HIV genome in the brain is asso-
ciated with neurodegenerative defects that occur in older pop-
ulations (Patrick et al. 2011).
Dr Spencer stated that the HIV genome in the brain takes
either the form of low-level replication producing the neuro-
toxins Tat, nef, and gag, or the genome is fully silenced (la-
tent). He discussed the epigenetic silencing of genes through
reversible mechanisms of methylation, deacetylation, and K-9
methylation. In chronic HIV encephalitis (HIVE), viral geno-
mic expression occurs in microglia and astrocytes via binding
of Sp1 protein to the promoter region. This, in turn drives HIV
genome expression through the p300 protein, via the NUCC1
promoter. By contrast, in the latent state, Sp1 binds the adaptor
protein BCL11b. This promotes DNAmethylation via a num-
ber of mechanisms resulting in histone modification confer-
ring a latent state with no genomic expression.
Dr Spencer described his group’s recently published
clinico-pathological study of 32 HIV+ patients whose brains
were classified at postmortem according to the levels of HIV
DNA, RNA and p24 antigen present (Desplats et al. 2013).
Twelve patients had no DNA, RNA, or p24 antigen detected
and were classified as controls. None of the controls had neu-
ropathological findings and of those evaluable, 56 % had
neurocognitive impairment (NCI). Ten patients were classi-
fied as having latent HIV infection with high levels of DNA
but no HIV RNA or p24 present. A proportion of patients
classified as latent had astrogliosis and 75 % of those
evaluable had NCI. Finally, 10 patients were classified as be-
ing HIVE cases because they had high levels of DNA, RNA
and p24 antigen. The HIVE cases had classical histopatholog-
ical changes of HIVE and severe NCI was seen in this patient
group (Desplats et al. 2013). Immunocytochemical and immu-
noblot analyses showed that, compared to those classified as
controls, patients classified as either latent or HIVE had re-
duced synaptic neuronal markers (MAP2 and synaptophysin),
increased levels of inflammation based on astroglial (GFAP)
and microglial (Iba-1) markers and decreased levels of the
neuronal autophagy marker, LC-3 (Desplats et al. 2013).
Interestingly, patients classified as latent had higher levels
of BCL11b present in neurons and microglial cells compared
to controls or HIVE patients. As a corollary, levels of BCL11b
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were higher in the CSF of controls and latent patients versus
HIVE patients, with CSF p24 Ag detected only in HIVE pa-
tients. Furthermore, latent patients had significantly higher
levels of the other chromatin modifiers HP1γ, MeCP2, and
HDAC1, involved in silencing genomic expression. Finally,
the authors looked for expression of other factors that are
transcriptionally regulated by BCL11B. They found that there
was dysregulation of expression in the patients’ brains of a
number of inflammatory markers including IL-6 and TNF-α.
Using these findings, the authors have developed the follow-
ing hypothesis. They reason that high levels of BCL11b present
in HIV-infected microglia and astrocytes that are required to
suppress active HIV infection in these cells, lead to the cells
producing increased levels of pro-inflammatory cytokines such
as IL-6 and TNF-α. In turn, these cytokines affect nearby neu-
rons which, through MAPkinase signalling (Zhang et al. 2012)
leads to sumoylation (or the stabilization) and accumulation of
BCL11B within neurons; in turn, this leads to neuronal dysreg-
ulation. Ultimately, this would contribute to the increased levels
of A-β protein, and α-synuclein that they observed also in this
patient group. It also potentially explains the high levels of
BCL11B that they observed in the neurons of these patients,
which cannot be due to suppression of latent neuronal HIV
DNA, as neurons do not support HIV infection.
Finally, Dr Spencer described their current efforts to devel-
op an in vitro cellular model of latency to assess BCL11B
impact on microglial and neuronal cells and how to reactivate
latently infected cells in the brain.
Dr. Churchill started her presentation by noting that astro-
cytes are neuroglial cells that arise from the ectoderm, astro-
cytes are the most abundant cells in the brain and are respon-
sible for maintaining brain homeostasis. Astrocytes have
broad ranging regulatory effects including influences on neu-
rotrophic factors to promote neuronal survival and
myelination, on the extracellular matrix to promote synapto-
genesis and neurogenesis, angiogenic factors, and endothelial
cells to regulate the blood brain barrier, regulation of brain
glycogen energy reserves, extracellular ions in the parenchy-
ma, and neurotransmitter regulation. Many of these regulatory
functions are disrupted in HIV infection. Astrocytes lack the
usual entry mechanism for HIV, CD4 receptors, so the entry of
HIV into astrocytes is CD4 receptor independent. Several po-
tential entry mechanisms were reviewed including the man-
nose receptor (Liu et al. 2004), direct entry by cell to cell
contact (Nath et al. 1995), CCR5 DC SIGN-dependent endo-
cytosis (Deiva et al. 2006), endocytic uptake including CD81-
dependent vesicle formation (Clarke et al. 2006; Gray et al.
2014). Prior studies have documented HIV DNA by PCR/in
situ and laser capture microdissection (Takahashi et al. 1996;
Sharer et al. 1996; An et al. 1999; Churchill et al. 2006).
Astrocyte-specific HIV sequences have been demonstrated
suggesting unique perhaps compartmentalized infection in
these cells compared to other cell hosts (Thompson et al.
2004; Churchill et al. 2009). Increasing HIV DNA in astro-
cytes is correlated with HIV-associated dementia, an impor-
tant clinical finding (Churchill et al. 2009). Interestingly, in-
fection with HIV was found to be correlated with proximity to
macrophages, and to endothelial cells (Churchill et al. 2009).
Astrocytes support latent infection which appears independent
of treatment with ART. HIV+ astrocytes have been document-
ed in neurologically asymptomatic patients, and are correlated
with decreasing CD4 cell counts. Dr Churchill noted the avail-
able indirect evidence for ongoing replication of HIV in the
CNS during cART, citing data on biomarkers such as neuro-
filament light (NFL) and s100B are still increased in patients
on cART over normal controls. Dr Churchill presented inter-
esting data on the potential neurotoxicity of several com-
pounds to reactivate latent HIV infection. She reviewed data
from her lab on the relative toxicity in cell culture assays for
panobinostat, romidepsin, vorinostat, HMBA, disulfarim, JQ-
1, and chaetocin. These agents are of use in reactivation of
latent HIV, but little is known about their ability to reactivate
latent virus in astrocytes. Dr Churchill noted the differential
penetration of antiretrovirals into the CNS, and went on to
present data on the relative efficacy of the antiretrovirals
abacavir, lamivudine, zidovudine, stavudine, efavirenz,
etravirine, nevaripine, and raltegravir in reducing HIV repli-
cation in astrocytes compared to monocyte-derived macro-
phages and peripheral blood mononuclear cells. She found
that there was reduced efficacy of lamivudine, stavudine,
and zidovudine in astrocytes relative to macrophages and
PBMCs (Gray et al. 2013). She noted that astrocytes were
an important target in latent infection, and many questions
remain regarding latent HIV in astrocytes and more research
needs be done in this area.
The second half of the second session was devoted to an-
imal models with two presentations, one from Dr J Victor
Garcia on the humanized mouse model, followed by Dr
Mankowski with the SIV macaque model.
Dr J Victor Garcia presented on his work on the BLT
mouse model (Wege et al. 2008). He noted that HIV-1 has
been associated with severe neurological issues, and that even
with advanced cART, neurological functioning is still compro-
mised although symptoms are milder. He reviewed the Trojan
horse model of HIVentry into the CNS, through trafficking of
HIV-infected T cells. He noted that there are many questions
to be resolved about HIV CNS infection including the exact
mechanism of how HIV enters the brain, what cell types are
involved, the kinetics of CNS infection, whether astrocytes
and microglia are latently infected cells and indeed what cells
are infected. He noted that these questions cannot be answered
in humans, as sampling of the CNS through brain biopsy is not
feasible. Therefore, an animal model with the necessary char-
acteristic to test the hypotheses is needed. Animal models
have the ability to provide samples of all types from multiple
compartments, where there is complete rigorous scientific
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control of the system. While non-human primate models are
available, they have limitations of expense and are not human.
Dr Garcia reviewed the strengths and limitations of the
existing mouse models including SCID-HIVE, huPBMC,
huPBL/HIVE, and huNSG (Honeycutt et al. 2014). Dr Garcia
then presented the humanized BLT mouse model, created by
implanting human thymus and liver tissues under the kidney
capsule of immunodeficient mice. These animals are also giv-
en an autologous stem cell transplant from those same liver
tissues, resulting in robust and systemic human immune cell
reconstitution in these animals which are readily infectable
withHIV viamultiple routes. He has characterized the human-
ized BLT mouse brain to demonstrate that it recapitulates key
characteristics of the human brain. The model has human he-
matopoietic cell populations, CD4+, CD8+, B, myeloid cells,
dendritic cells, and CD68+ (macrophages) in relatively appro-
priate concentrations for the relevant research aims. In his
experimental design, R5 tropic viruses are utilized in the ex-
posure routes of vaginal, rectal, oral, and intravenous. Persis-
tent HIV infection in the brains of the BLT mice has been
shown. He noted that CD8+ cell subset relatively expanded
in the CNS while the proportion of CD4+ cells decreased, and
the shift occurred rapidly after infection. Antiretroviral treat-
ment with four different regimens in the BLT mice model has
been studied including TDF/FTC/DTG, RAL/TDF/FTC,
RPV/DTG/FTC, and RPV/DTG with daily administration
for 6–10 weeks. Dramatic reductions in both plasma and brain
HIV RNAwere demonstrated with ART, and the relative per-
centages of CD4+, CD8+, and the ratio are reconstituted and
similar to uninfected mice. The BLTmice have been shown to
be an extremely useful tool in investigating NeuroAIDS.
Dr. Mankowski presented on the SIV macaque model of
HIV CNS latency. He opened his talk by noting that the Mis-
sissippi baby who was thought to be cured was no longer in
remission. He cited Dr. Fauci’s comment on how recalcitrant
the virus is and noted that we have not identified all the cel-
lular reservoirs for HIV. He reviewed the early characteriza-
tion of HIV as a member of the lentivirus family, that HIV
establishes latency in macrophages, and the role of macro-
phages in latency. He noted that the natural hosts of SIV are
in multiple African primate species such as the chimpanzee,
whereas the Asian macaque is an abnormal host. The pigtailed
macaque is the model of HAND that has demonstrated that
SIV viral loads in the CSF are higher in those animals that
develop encephalitis, compared to lower CSF viral loads in
those without encephalitis. cART is effective in this SIV ma-
caque model, with significant plasma and CSF viral RNA
decay after treatment initiation. While the viral RNA reser-
voirs are reduced with treatment in this model, the viral
DNA reservoir is not reduced. Biomarkers clinically relevant
in HAND, including CSF NFL, CSF neopterin and plasma
CD163 are similarly elevated in the SIV model. Dr
Mankowski presented data that CNS penetrant ART reduced
viral load in plasma and CSF in the SIV model, and that
associated CSF inflammatory biomarkers such as MCP-1
and IL-6 were also reduced. Data were presented that demon-
strated the greatly increased virulence and morbidity of SIV in
pigtail macaques relative to rhesus macaques, including the
development of SIV CNS disease. CCR5 inhibitors such as
maraviroc (MVC) in HAND are potentially very beneficial
given their high CNS penetrance, low neurotoxicity, ability
to control viremia, and decrease immune activation. A study
of MVC in SIV was presented with controls, where SIV in
CSF and plasma was reduced by MVC monotherapy. Of in-
terest, in addition to greatly reducing SIV RNA in the brain,
SIV DNA levels in the brain reflective of latent SIV were also
significantly lowered by MVC. Other potential beneficial out-
comes of MVC treatment in the brain included decreased
macrophage activation, lower APP accumulation, reduced
CNS inflammation with both TNFα and CCL2 RNA expres-
sion lower in the brain with MVC treatment. Dr Mankowski
summarized that the addition of CCR5 inhibitors including
MVC to cART may prevent and treat HAND and also may
reduce persistent CNS reservoirs of HIV (Kelly et al. 2013).
Session 3: the brain as a reservoir and sanctuary
This session opened with Dr Gelman discussing the neuropa-
thology in virally suppressed patients followed by Tat detection
and expression in virally suppressed patients by Dr Johnson.
Dr Gelman began with data comparing HIV DNA versus
HIV RNA in brains from well-characterised patients. He ref-
erenced his recent publications (Gelman et al. 2012a; 2013)
where the point is made that latent HIV DNA in the central
nervous system is not related to HAND as opposed to HIV
RNA. He went further to make the point that HIV DNA dis-
tribution in the brain is not identical to HIV RNA and that the
frontal neocortex has the highest burden of HIV DNA. He
then showed data relating to macrophage markers with high
versus low integrated HIV DNA. The macrophage markers
that were associated with a high integrated HIV DNA were
IRF4, CCL2 IL10, and CLEC4A. Macrophage markers that
were not more common with high levels of HIV integrated
DNAwere AIF1, S100A9, CD16, CD14, CD163, and CD68.
There were further data on IRF4 and how it is involved in
macrophage polarization into the macrophage inflammatory
phenotype, namely M1, versus the angiogenic wound healing
phenotype, namely M2. Data were then presented localizing
IRF4 to leptomeningeal macrophages. Dr Gelman then fo-
cused on evidence that the neuropathology of HAND in viral-
ly suppressed patients was a neurochemical disorder without
real evidence of neurodegeneration. These data were derived
from the PLoS One publication (Gelman et al. 2012a) and
showed that GABAergic transmission in the prefrontal area
was low, seemingly related to GAD67 downregulation in the
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absence of any encephalitis. Similarly, the prefrontal dopami-
nergic system was also abnormal with downregulation of
DRD2L messenger RNA in virally suppressed patients. In-
deed, low dopamine receptor 2 expression was found, even
in patients who were neuropsychologically normal (Gelman
et al. 2012b).
He then summarized the data for neurotransmitter abnormal-
ities, focusing on DRD2L and enkephalin and the GABAergic
system, particularly GAD1. Of these, only the enkephalin sys-
tem was associated with HIVencephalitis while no system was
more broadly associated with HAND. These systems were all
abnormally low in the context of HIV infection per se.
Dr Gelman therefore concluded that integrated HIV DNA
in the brain tissue was linked to the expression of selected
macrophage products but not pan macrophage markers and
that the neuropathology of HAND in virally suppressed pa-
tients was more a neurochemical disorder rather than one of
neurodegeneration.
Dr Johnson then reviewed the data relating to HIV and
chronic inflammation and its consequences including cogni-
tive decline. The potential causes for chronic inflammation
and T-cell activation were presented with evidence pointing
to a key role for Tat. It was emphasized that current antiretro-
viral drugs do not inhibit Tat production as they have no effect
on post integration transcription of viral components such as
Tat. It was further emphasized that Tat is able to exit the cell
and alter the cellular function of neighboring cells that are
uninfected. The recent article by Johnson et al. (2013)
was noted with in vitro evidence of darunavir’s inability
to inhibit Tat production, as well as its ability to induce IL17 in
Tcells, leading to the hypothesis that Tat could activate T cells
and produce pro-inflammatory cytokines that contribute to
both inflammation and neuronal disorders.
Dr Johnson then focused on the immune reconstitution
inflammatory syndrome and presented cases that were de-
tailed in her recent publication (Johnson et al. 2013). These
demonstrated CNS IRIS with no evidence of productive HIV
infection but with evidence of Tat on cerebral biopsy.
As a consequence of these findings, the study was extended
to determine if Tat could be playing a role in the development
of HAND. ATat ELISA that was functional in the cerebrospi-
nal fluid was developed. Dr Johnson noted that the assay was
robust with an intra-plate variability of 4.446% and inter-plate
variability of 7.56 %. The assay itself however has not been
optimized for blood and is, at present, appropriate for use in
only some HIV clades. Two cohorts of patients were
discussed. The first comprised eight patients where three had
Tat detectable in the cerebrospinal fluid. The second cohort
was that of 57 patients from the North East America Dementia
Cohort Study. Tat was detected in 42 % of these with some
relationship to HAND severity.
In the discussion of the presentation, comment was made
that a third cohort from Sydney also had shown detectable
levels of Tat in the cerebrospinal fluid, but at a much lower
rate. Further commentary focused on whether Tat could cross
the blood brain barrier and the significance of the amounts of
Tat that were present in the cerebrospinal fluid: Tat may enter
the cerebrospinal fluid from HIV-infected cells in the cerebro-
spinal compartment, brain parenchyma, or directly across the
blood-cerebrospinal fluid barrier via the choroid plexus.
Session 4: oral abstract presentations
This session was driven by three abstracts that had been se-
lected for oral presentation.
Dr Churchill described data relating to HIV-1 LTRs isolat-
ed from the CNS having mutations in the core promoter motif
(Sp1 sites). These resulted in a reduced capacity to bind Sp1
protein and reduced transcriptional activity. It was emphasized
that such unique regulatory mechanisms in the CNS will need
to be considered with current HIV cure strategies as they in-
volve activation of HIV-1 transcription.
Dr Gray showed data that HIV-1 establishes transcriptional
latency in astrocytes in vitro and is responsive to the histone
deacetylase inhibitors romidepsin, and Panobinostat, as well
as JQ-1 while vorinostat, HMBA, disulfiram, and chaetocin
showed minimal LTR activation. With the exception of
chaetocin, none of these showed any significant toxicity. As
such, these drugs could be considered in HIV eradication
strategies.
Dr Cysique presented data on the relationship between the
HIV DNA reservoir in peripheral blood mononuclear cells
and HAND. In contradistinction to HAD, the more severe
form of HAND, there was no relationship between non-
demented HAND and HIV DNA in peripheral blood mono-
nuclear cells. These data suggest that non-demented HAND is
more related to intrinsic brain HIV disease rather than system-
ic HIV disease. This has direct impact on the approach to be
taken for eradication strategies.
Session 5: CNS eradication—risks and outcomes
This session was comprised of two presentations, one fromDr
Robertson on initial clinical outcomes, and the second by Dr
Brew on barriers and risk identification.
Dr Robertson presented on initial clinical outcomes asso-
ciated with the kick and kill strategy for curing HIV. This
strategy seeks to reactivate latent HIV then kills the activated
and replicating virus with antiretrovirals. HIV gains entry into
the CNS very early in infection. Studies during acute infection
have demonstrated HIV RNA in CSF and plasma within days
(Valcour et al. 2012; Spudich et al. 2011). Relative to plasma
HIV RNA, CSF HIV RNA concentrations are generally lower
but consistently present. Prior work by Schnell et al. (2010)
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provided evidence for different genetic sequences of HIV in
the CNS compared to plasma, or compartmentalization of
HIV. This compartmentalization was associated with HIV as-
sociated neurological disorder. Localized replication and com-
partmentalization has also recently been documented in pri-
mary HIV infection, as early as 4 months post infection, by the
Swanstrom lab in collaboration with Spudich and colleagues
(Sturdevant et al. 2014). Dr Robertson noted that if the virus is
compartmentalized in the CNS, then antiretrovirals will have
to penetrate the CNS to treat HAND. Letendre has defined and
updated a CNS penetration efficacy ranking commonly in use
for ART (Letendre 2011). It will also be necessary for eradi-
cation agents to penetrate the CNS to be effective in compart-
mentalized virus. While CNS penetration is necessary for
eradication and treatment, there is potentially a double-edged
sword to this penetration into the CNS. There is evidence that
some ART can be neurotoxic as shown in vitro (Robertson
et al. 2012a). While controversial, some clinical studies have
found that neurocognitive performance improved with cessa-
tion of ART in an early treatment adoption group (Robertson
et al. 2012b), that CNS-penetrating regimens did not improve
neurocognition in those with impairment (Marra et al. 2009), a
large observational study found penetrating ART associated
with HAD (Caniglia et al. 2014). As ART may be neurotoxic,
there should be concern that eradication agents used in
reactivating the virus may also be neurotoxic. Little is known
about the neurotoxicity of these agents, although some of the
first data available regarding relative toxicities of these agents
was presented by Churchill et al. at this meeting.
Histone deacetylase inhibitors are a potentially effective
class of drugs for the kick and kill strategy. Vorinistat is one
such HDAC inhibitor, which disrupts HIV latency and
upregulates HIV regulation (Archin et al. 2012a). Little is
known about the CNS efficacy and neurotoxicity of vorinostat
(VOR). The initial clinical study of VOR enrolled eight sub-
jects and found that VOR was effective in disrupting latency
(Archin et al. 2012b). In the follow-up study with repeated
dosing, a lack of induction of HIV viral replication by VOR
was noted over time. Dr Robertson reported the first study of
the CNS outcomes in VOR for reactivation of latent HIV, to
assess initial safety and efficacy. Five subjects were assessed
with a neurocognitive battery pre VOR administration and at
4 months, post 22 doses of VOR. The neurocognitive battery
assessed premorbid/language (WRAT-4 Reading), verbal
learning (HVLT-R), verbal memory (HVLT-R delay), finemo-
tor (Grooved Pegboard), speed of processing (Stroop Color,
Stroop Word, Trailmaking A, Digit Symbol), Attention/
Working Memory (Symbol Search), and executive functions
(Stroop Color-Word, Verbal fluency, Trailmaking B). There
was no evidence of decline from pre and post VOR adminis-
tration in global neurocognitive functioning or in specific do-
mains of functioning, indicating very preliminary safety in this
small sample. Dr Robertson noted that in future studies of
HAND, eradication and cure of HIV will need to address
CNS penetration, CNS efficacy, and neurotoxicity. Future
studies will need to include neurocognitive and neurological
assessments to assess safety and efficacy of these agents in the
eradication and cure of HIV.
Dr Brew discussed the barriers to HIV eradication when
HIV is present in the brain. These included the limited CNS
efficacy of cART in relation to the penetration of ARVs into
the brain, the limited and variable cellular efficacy especially
in astrocytes (Gray et al. 2013) and the inefficacy in
preventing post integration transcription so that potentially
neurotoxic viral components such as tat could still be pro-
duced as previously discussed (Johnson et al. 2013). More-
over, currently there are no validated tools by which to quan-
titate the amount of latent HIV in the brain. Biomarkers such
as magnetic resonance spectroscopy and BCL11b (Desplats
et al. 2013) require more extensive rigorous study. For exam-
ple, does a normal magnetic resonance spectroscopy mean
there are no significant amounts of HIV DNA in the brain?
The risks of HIVeradication relate to worsening of CNS viral
burden because current ARVs cannot completely control brain
HIV infection. This is pertinent to the “kick and kill” strategy
where there is “reawakening” of HIV from its latent state and
then killing, as well as the functional cure strategy. In both
scenarios, an IRIS phenomenon could develop, analogous to
that which occurred in Alzheimer’s disease with active immu-
nization against amyloid (Brew et al. 2013). Further risks were
discussed including the toxicity of therapies, both ARVs and
HDAC inhibitor drugs as well as the potential for off-target
effects especially modulation of gene activity. The solutions to
these issues have yet to be found but given that at most ap-
proximately half of HIV-infected patients do not have HAND
it would seem reasonable to focus on such patients for eradi-
cation therapies. Further, it may even be possible to include
patients with little or no HIV brain disease by targeting those
at seroconversion or at least early in the course of HIV disease.
The development of better cART regimens that have good
CNS penetration and block entry into cells as well as
inhibiting post integration transcription will allow the inclu-
sion of at least some HAND patients. The critical issue will be
the quantification of the HIV brain reservoir—those HAND
patients with a low burden may be able to tolerate mild IRIS.
There may be situations where mild neuronal loss will be an
acceptable “price” for HIV eradication, similar to the “chemo
brain” that some patients experience as a consequence of sys-
temic chemotherapy as treatment for a variety of cancers.
Session 6: current and future studies
Dr Jeymohan Joseph in this session dealt with NIMH priorities
and funding for HIV eradication with the focus on the brain
along with contributions from Drs Dianne Rausch and Deborah
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Colosi. Dr Joseph stated that the Division of AIDS Research at
NIMH was keen to support research directed goals to:
& Identify and characterize persistent HIV-1 in CNS-derived
cells in the setting of suppressive cART,
& Determine the mechanisms involved in the temporal es-
tablishment, maintenance, and resurgence of persistent
HIV-1 in the CNS in relationship to the timing of cART
& Develop physiologically relevant animal models and
CNS-based cellular assays that recapitulate HIV-1 persis-
tence and latency in the presence of effective cART
& Assess current and emerging eradication approaches to
determine if they have successfully reactivated persistent
HIV from CNS-derived cells
& Assess CNS toxicity and any adverse impact of current
and emerging eradication strategies
The strategies to achieve these goals included orga-
nizing HIV CNS eradication focused brainstorming
workshops, issuance of funding opportunities announce-
ments (FOAs), and provision of resources for HIV CNS
eradication research. NIMH has partnered with other
sister institutes such as NIAID, NINDS, and NIDA in
the issuance of FOAs targeted at stimulating research on
HIV persistence in the brain. Dr Joseph also described
the availability of tissue resources for CNS Eradication
research from the National NeuroAIDS Tissue Consor-
tium (NNTC) (https://nntc.org/). The NNTC, supported
by NIMH and NINDS, had four Clinical Sites in the US
and can provide brain, CSF, and other tissue samples to
qualified investigators.
Conclusions
The symposium concluded that the evidence for the
brain as a significant HIV reservoir, while compelling,
still requires further substantiation with attention to con-
troversial issues such as latent infection of intrinsic
brain cells, and that the brain may be a significant
HIV reservoir only in some patients. Further research
also needs to focus on the development of biomarkers
to identify and quantify the HIV reservoir in the brain.
Finally, the brain should be a primary concern in the
development of new eradication strategies.
Conflict of interest Bruce Brew has received research funding and
speaker honoraria from Viiv and speaker honoraria from Boehringer
Ingelheim.
Edwina Wright has received funding from Boehringer Ingelheim for
research and she has received funding from ViiV for lectures and devel-
opment of educational resources which has been used for research pur-
poses only.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
AnSF, GrovesM,Giometto B, Beckett AA, Scaravilli F (1999) Detection
and localisation of HIV-1 DNA and RNA in fixed adult AIDS brain
by polymerase chain reaction/in situ hybridisation technique. Acta
Neuropathol 98(5):481–487
Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2005)
Influence of HAARTon HIV-related CNS disease and neuroinflam-
mation. J Neuropathol Exp Neurol 64(6):529–536
Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD,
Crooks AM et al (2012a) Administration of vorinostat disrupts
HIV-1 latency in patients on antiretroviral therapy. Nature
487(7408):482–485
Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD,
Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC,
Richman DD, HudgensMG, Bosch RJ, Coffin JM, Eron JJ, Hazuda
DJ, Margolis DM (2012b) Administration of vorinostat disrupts
HIV-1 latency in patients on antiretroviral therapy. Nature
487(7408):482–485, Erratum in: Nature 2012 Sep 20;489(7416):
460
Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM
(2014) Eradicating HIV-1 infection: seeking to clear a persistent
pathogen. Nat Rev Microbiol 12(11):750–764
Barouch DH, Deeks SG (2014) Immunologic strategies for HIV-1 remis-
sion and eradication. Science 345(6193):169–174
Brew BJ, Gray L, Lewin SR, Churchill M (2013) Is specific HIV eradi-
cation from the brain possible or needed? Exp Opin Biol Ther 13(3):
403–409
Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF (2014)
New ex vivo approaches distinguish effective and ineffective single
agents for reversing HIV-1 latency in vivo. Nat Med 20(4):425–429
Butler KM,Gavin P, Coughlan S, Rochford A, Donagh SM,Cunningham
O, PoulsomH,Watters S, Klein N (2014) Rapid Viral Rebound after
4 Years of Suppressive Therapy in a Seronegative HIV-1 Infected
Infant Treated from Birth. Pediatr Infect Dis J. [Epub ahead of print]
BuzonMJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC et al
(2010) HIV-1 replication and immune dynamics are affected by
raltegravir intensification of HAART-suppressed subjects. Nat
Med 16(4):460–465
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A,
van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR,
Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC,
Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J,
Costagliola D, Hernán MA, HIV-CAUSAL Collaboration (2014)
Antiretroviral penetration into the CNS and incidence of AIDS-
defining neurologic conditions. Neurology 83(2):134–141
Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC
(2005) Cellular APOBEC3G restricts HIV-1 infection in resting
CD4+ T cells. Nature 435(7038):108–114
Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D,
Mullins JI et al (2000) Relationship between pre-existing viral res-
ervoirs and the re-emergence of plasma viremia after discontinuation
of highly active anti-retroviral therapy. Nat Med 6(7):757–761
Churchill MJ, Gorry PR, Cowley D, Lal L, Sonza S, Purcell DF,
Thompson KA, Gabuzda D, McArthur JC, Pardo CA, Wesselingh
SL (2006) Use of laser capture microdissection to detect integrated
332 J. Neurovirol. (2015) 21:322–334
HIV-1 DNA in macrophages and astrocytes from autopsy brain
tissues. J Neurovirol 12(2):146–152
Churchill MJ,Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew
BJ, Gorry PR (2009) Extensive astrocyte infection is prominent in
human immunodeficiency virus-associated dementia. Ann Neurol
66(2):253–258
Clarke JN, Lake JA, Burrell CJ, Wesselingh SL, Gorry PR, Li P (2006)
Novel pathway of human immunodeficiency virus type 1 uptake and
release in astrocytes. Virology 348(1):141–155
Cockerham LR, Siliciano JD, Sinclair E, O'Doherty U, Palmer S, Yukl
SA et al (2014) CD4+ and CD8+ T cell activation are associated
with HIV DNA in resting CD4+ T cells. PLoS One 9(10):e110731
Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E et al (2011)
Raltegravir treatment intensification does not alter cerebrospinal flu-
id HIV-1 infection or immunoactivation in subjects on suppressive
therapy. J Infect Dis 204(12):1936–1945
Dahl V, Gisslen M, Hagberg L, Peterson J, Shao W, Spudich S et al
(2014a) An example of genetically distinct HIV type 1 variants in
cerebrospinal fluid and plasma during suppressive therapy. J Infect
Dis 209(10):1618–1622
Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW (2014b)
Low levels of HIV-1 RNA detected in the cerebrospinal fluid after
up to 10 years of suppressive therapy are associated with local im-
mune activation. AIDS 28(15):2251–2258
Deiva K, Khiati A, Hery C, Salim H, Leclerc P, Horellou P, Tardieu M
(2006) CCR5-, DC-SIGN-dependent endocytosis and delayed re-
verse transcription after human immunodeficiency virus type 1 in-
fection in human astrocytes. AIDS Res Hum Retrovir 22(11):1152–
1161
Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, Swanson
MD et al (2012) Generation of HIV latency in humanized BLTmice.
J Virol 86(1):630–634
Desplats P, Dumaop W, Smith D, Adame A, Everall I, Letendre S et al
(2013) Molecular and pathologic insights from latent HIV-1 infec-
tion in the human brain. Neurology 80(15):1415–1423
Dinoso JB, Rabi SA, Blankson JN, Gama L,Mankowski JL, Siliciano RF
et al (2009) A simian immunodeficiency virus-infected macaque
model to study viral reservoirs that persist during highly active an-
tiretroviral therapy. J Virol 83(18):9247–9257
Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J
et al (2009) Macrophage delivery of nanoformulated antiretroviral
drug to the brain in a murine model of neuroAIDS. J Immunol
183(1):661–669
Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B et al
(2010) HIV-1 viral escape in cerebrospinal fluid of subjects on sup-
pressive antiretroviral treatment. J Infect Dis 202(12):1819–1825
Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, Solomon A
et al (2007) The CD16+ monocyte subset is more permissive to
infection and preferentially harbors HIV-1 in vivo. J Immunol
178(10):6581–6589
Fischer-Smith T, Croul S, SverstiukAE, Capini C, L'HeureuxD, Regulier
EG et al (2001) CNS invasion by CD14+/CD16+ peripheral blood-
derived monocytes in HIV dementia: perivascular accumulation and
reservoir of HIV infection. J Neurovirol 7(6):528–541
Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM
et al (2012) No effect of raltegravir intensification on viral replica-
tion markers in the blood of HIV-1-infected patients receiving anti-
retroviral therapy. J Acquir Immune Defic Syndr 59(3):229–235
Garvey LJ, Pavese N, PolitisM, Ramlackhansingh A, Brooks DJ, Taylor-
Robinson SD et al (2014) Increased microglia activation in neuro-
logically asymptomatic HIV-infected patients receiving effective
ART. AIDS 28(1):67–72
Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey
JM, Masliah E, Commins DL, Brandt D, Grant I, Singer EJ, Levine
AJ, Miller J, Winkler JM, Fox HS, Luxon BA, Morgello S (2012a)
National NeuroAIDS Tissue Consortium. The National NeuroAIDS
Tissue Consortium brain gene array: two types of HIV-associated
neurocognitive impairment. PLoS One 7(9):e46178
Gelman BB, Lisinicchia JG, Chen T, Johnson KM, Jennings K, Freeman
DH Jr, Soukup VM (2012b) Prefrontal dopaminergic and
enkephalinergic synaptic accommodation in HIV-associated
neurocognitive disorders and encephalitis. J Neuroimmune Pharm
7(3):686–700
Gelman BB, Lisinicchia JG, Morgello S, Masliah E, Commins D, Achim
CL, Fox HS, Kolson DL, Grant I, Singer E, Yiannoutsos CT,
Sherman S, Gensler G, Moore DJ, Chen T, Soukup VM (2013)
Neurovirological correlation with HIV-associated neurocognitive
disorders and encephalitis in a HAART-era cohort. J Acquir
Immune Defic Syndr 62(5):487–495
Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of
AIDS. Nat Rev Immunol 5(1):69–81
Gray LR, Tachedjian G, Ellett AM, Roche MJ, ChengW-J, Guillemin G,
Brew BJ, Turville SG, Wesselingh SL, Gorry PR, Churchill MJ
(2013) The NRTIs lamivudine, stavudine and zidovudine have re-
duced HIV-1 inhibitory activity in astrocytes. PLoS One 8(4):
e62196
Gray LR, Turville SG, Hitchen TL, Cheng WJ, Ellett AM, Salimi H,
Roche MJ, Wesselingh SL, Gorry PR, Churchill MJ (2014) HIV-1
entry and trans-infection of astrocytes involves CD81 vesicles.
PLoS One 9(2):e90620
Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R et al
(2013) Increase in 2-long terminal repeat circles and decrease in D-
dimer after raltegravir intensification in patients with treated HIV
infection: a randomized, placebo-controlled trial. J Infect Dis
208(9):1436–1442
Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH
et al (2014) Antiretroviral-free HIV-1 remission and viral rebound
after allogeneic stem cell transplantation: report of 2 cases. Ann
Intern Med 161(5):319–327
Ho YC, Shan L, Hosmane NN,Wang J, Laskey SB, Rosenbloom DI et al
(2013) Replication-competent noninduced proviruses in the latent
reservoir increase barrier to HIV-1 cure. Cell 155(3):540–551
Honeycutt JB, Sheridan PA, Matsushima GK, Garcia JV (2014)
Humanized mouse models for HIV-1 infection of the CNS. J
Neurovirol
Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K et al
(2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-
cell transplantation. N Engl J Med 360(7):692–698
Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, Hasbun R,
Nath A (2013) Induction of IL-17 and nonclassical T-cell activation
by HIV-Tat protein. Proc Natl Acad Sci U S A 110(33):13588–
13593
Kelly KM, Beck SE, Metcalf Pate KA, Queen SE, Dorsey JL, Adams RJ,
Avery LB, Hubbard W, Tarwater PM, Mankowski JL (2013)
Neuroprotective maraviroc monotherapy in simian immunodefi-
ciency virus-infected macaques: reduced replicating and latent SIV
in the brain. AIDS 27(18):F21–F28
Letendre S (2011) Central nervous system complications in HIV disease:
HIV-associated neurocognitive disorder. Top Antivir Med 19(4):
137–142
Letendre SL, Ellis RJ, Ances BM, McCutchan JA (2010) Neurologic
complications of HIV disease and their treatment. Top HIV Med
Publ Int AIDS Soc USA 18(2):45–55
Liu Y, Liu H, Kim BO, Gattone VH, Li J, Nath A, Blum J, He JJ (2004)
CD4-independent infection of astrocytes by human immunodefi-
ciency virus type 1: requirement for the human mannose receptor.
Journal Virology 2004;78(8):4120–33. Erratum in. J Virol 78(13):
7288–7289
Llibre JM, BuzonMJ, Massanella M, Esteve A, Dahl V, Puertas MC et al
(2012) Treatment intensification with raltegravir in subjects with
sustained HIV-1 viraemia suppression: a randomized 48-week
study. Antivir Ther 17(2):355–364
J. Neurovirol. (2015) 21:322–334 333
Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ,
Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K,
AIDS Clinical Trials Group 736 Study Team (2009) Impact of com-
bination antiretroviral therapy on cerebrospinal fluid HIV RNA and
neurocognitive performance. AIDS 23(11):1359–1366
McElrath MJ, Steinman RM, Cohn ZA (1991) Latent HIV-1 infection in
enriched populations of blood monocytes and T cells from seropos-
itive patients. J Clin Investig 87(1):27–30
Mikovits JA, Lohrey NC, Schulof R, Courtless J, Ruscetti FW (1992)
Activation of infectious virus from latent human immunodeficiency
virus infection of monocytes in vivo. J Clin Invest 90(4):1486–1491
Nath A, Hartloper V, FurerM, FowkeKR (1995) Infection of human fetal
astrocytes with HIV-1: viral tropism and the role of cell to cell
contact in viral transmission. J Neuropathol Exp Neurol 54(3):
320–330
Patrick C, Crews L, Desplats P, Dumaop W, Rockenstein E, Achim CL
et al (2011) Increased CDK5 expression in HIVencephalitis contrib-
utes to neurodegeneration via tau phosphorylation and is reversed
with Roscovitine. Am J Pathol 178(4):1646–1661
Prinz M, Priller J (2014) Microglia and brain macrophages in the molec-
ular age: from origin to neuropsychiatric disease. Nat Rev Neurosci
15(5):300–312
Robertson K, Liner J, Meeker RB (2012a) Antiretroviral neurotoxicity. J
Neurovirol 18(5):388–399
Robertson K, Jiang H, Kumwenda J, Supparatpinyo K, Evans S,
Campbell TB, Price R, Tripathy S, Kumarasamy N, La Rosa A,
Santos B, 5199 study team, Silva MT, Montano S, Kanyama C,
Faesen S, Murphy R, Hall C, Marra CM, Marcus C, Berzins B,
Allen R, Housseinipour M, Amod F, Sanne I, Hakim J,
Walawander A, Nair A, AIDS Clinical Trials Group (2012b)
Improved neuropsychological and neurological functioning across
three antiretroviral regimens in diverse resource-limited settings:
AIDS Clinical Trials Group study a5199, the International
Neurological Study. Clin Infect Dis 55(6):868–76
Schnell G, Price RW, SwanstromR, Spudich S (2010) Compartmentalization
and clonal amplification of HIV-1 variants in the cerebrospinal fluid
during primary infection. J Virol 84(5):2395–2407
Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R (2011) HIV-1
replication in the central nervous system occurs in two distinct cell
types. PLoS Pathog 7(10):e1002286
Sharer LR, Saito Y, Da Cunha A, Ung PC, Gelbard HA, Epstein LG,
Blumberg BM (1996) In situ amplification and detection of HIV-1
DNA in fixed pediatric AIDS brain tissue. HumPathol 27(6):614–617
Sonza S, Maerz A, Deacon N, Meanger J, Mills J, Crowe S (1996)
Human immunodeficiency virus type 1 replication is blocked prior
to reverse transcription and integration in freshly isolated peripheral
blood monocytes. J Virol 70(6):3863–3869
Sonza S, Mutimer HP, Oelrichs R, Jardine D, Harvey K, Dunne A et al
(2001) Monocytes harbour replication-competent, non-latent HIV-1
in patients on highly active antiretroviral therapy. AIDS 15(1):17–22
Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D,
Tambussi G, Cinque P, Hecht FM, Price RW (2011) Central nervous
system immune activation characterizes primary human immunode-
ficiency virus 1 infection even in participants with minimal cerebro-
spinal fluid viral burden. J Infect Dis 204(5):753–760
Sturdevant CB, Schnell G, Price RW, Spudich S, Swanstrom R (2014)
Replication of HIV-1 in the Central Nervous System of Adults Early
After Infection. Oral abstract #32 CROI
Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT,
Glass JD (1996) Localization of HIV-1 in human brain using poly-
merase chain reaction/in situ hybridization and immunocytochemis-
try. Ann Neurol 39(6):705–711
Teo I, Veryard C, Barnes H, An SF, Jones M, Lantos PL et al (1997)
Circular forms of unintegrated human immunodeficiency virus type
1 DNA and high levels of viral protein expression: association with
dementia andmultinucleated giant cells in the brains of patients with
AIDS. J Virol 71(4):2928–2933
Thompson KA, Churchill MJ, Gorry PR, Sterjovski J, Oelrichs RB,
Wesselingh SL, McLean CA (2004) Astrocyte specific viral strains
in HIV dementia. Ann Neurol 56(6):873–877
Thompson KA, Cherry CL, Bell JE, McLean CA (2011) Brain cell res-
ervoirs of latent virus in presymptomatic HIV-infected individuals.
Am J Pathol 179(4):1623–1629
Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S,
Suttichom D, Suwanwela NC, Jagodzinski L, Michael N, Spudich
S, van Griensven F, de Souza M, Kim J, Ananworanich J, RV254/
SEARCH 010 Study Group (2012) Central nervous system viral
invasion and inflammation during acute HIV infection. J Infect Dis
206(2):275–282
Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV (2008)
Functional and phenotypic characterization of the humanized BLT
mouse model. Curr Top Microbiol Immunol 324:149–165
Williams KC, Corey S,Westmoreland SV, Pauley D, Knight H, deBakker
C et al (2001) Perivascular macrophages are the primary cell type
productively infected by simian immunodeficiency virus in the
brains of macaques: implications for the neuropathogenesis of
AIDS. J Exp Med 193(8):905–915
Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Epling L et al (2013)
The distribution of HIV DNA and RNA in cell subsets differs in gut
and blood of HIV-positive patients on ART: implications for viral
persistence. J Infect Dis 208(8):1212–1220
Zhang LJ, Vogel WK, Liu X, Topark-Ngarm A, Arbogast BL, Maier CS
et al (2012) Coordinated regulation of transcription factor Bcl11b
activity in thymocytes by the mitogen-activated protein kinase
(MAPK) pathways and protein sumoylation. J Biol Chem 287(32):
26971–26988
Zhu T, Muthui D, Holte S, Nickle D, Feng F, Brodie S et al (2002)
Evidence for human immunodeficiency virus type 1 replication
in vivo in CD14(+) monocytes and its potential role as a source of
virus in patients on highly active antiretroviral therapy. J Virol 76(2):
707–716
334 J. Neurovirol. (2015) 21:322–334
